Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17138255 | 1.00 | CYP2D6 (0.31) | CYP2D6 | |
| SCHEMBL7068189 | 0.80 | CYP2D6 (0.35) | CYP2D6 | |
| SCHEMBL17138262 | 0.76 | DPP4 (0.31) | — | |
| SCHEMBL25721685 | 0.76 | CYP2D6 (0.33) | CYP2D6 | |
| SCHEMBL21708027 | 0.76 | CYP2D6 (0.33) | CYP2D6 | |
| SCHEMBL14962705 | 0.76 | CYP2D6 (0.33) | CYP2D6 | |
| SCHEMBL18811712 | 0.76 | CYP2D6 (0.33) | CYP2D6 | |
| SCHEMBL21708028 | 0.76 | CYP2D6 (0.33) | CYP2D6 | |
| SCHEMBL17337593 | 0.76 | CYP2D6 (0.33) | CYP2D6 | |
| SCHEMBL17337592 | 0.76 | CYP2D6 (0.33) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158307-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | ACES Pharma Inc. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9260478-B2 | Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis | HU SHANGHUI (US) | 2016-02-16 | — | — | US | disclosed |
| WO-2015154029-A1 | POTENT AND EFFICIENT CYTOTOXIC PEPTIDES AND ANTIBODY-DRUG CONJUGATES THEREOF | ACES Pharma Inc. (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20150284425-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | ACES Pharma Inc. (US) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158307-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | NGLY1, VIP, DNPEP | CYP2D6 3313/4885 |
| US-20150284425-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | NGLY1, VIP, DNPEP | CYP2D6 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.